Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freeport-McMoRan Inc (FCX) vs GSK plc (GSK) Price & Performance

Freeport-McMoRan IncTrade

Price performance (Past 24H)

Key statistics

Freeport-McMoRan Inc vs GSK plc — how do they compare? Freeport-McMoRan Inc trades at $68.98 (market cap $96.42B), while GSK plc trades at $50.43 (market cap $102.60B). The key difference: Freeport-McMoRan Inc and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

FCXGSK
Market Cap
$96.42B$102.60B
Sector
Basic MaterialsHealth
52-Week High
$71.73$61.18
52-Week Low
$35.34$38.22
Enterprise Value
$102.70B$123.04B
Dividend Yield
0.87%3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freeport-McMoRan Inc

FCX trades at $69.18, down 1.92% today but maintains a bullish technical outlook with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.68 exceeding expectations. Revenue growth remains stable at $25.9B, while profitability metrics show improvement with net income margin expanding to 11.38%. Recent news highlights operational strength at Grasberg mine and positive copper market tailwinds.

FCX presents a compelling investment case with analyst consensus pointing to 6.8% upside to the $73.85 price target. The company's growth initiatives and copper market exposure provide tailwinds, though investors should monitor commodity price volatility and execution risks in expansion projects. With 61% of analysts rating the stock a Buy, institutional sentiment remains positive despite recent price weakness.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Freeport-McMoRan Inc

Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia

Read more on FCX

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK